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Abstract
Background: In this study, we examined alterations in the hypothalamic reward system related to high-fat diet (HFD)
preferences. We previously reported that hypothalamic 2-arachidonoylglycerol (2-AG) and glial fibrillary acid protein (GFAP)
were increased after conditioning to the rewarding properties of a HFD. Here, we hypothesized that increased 2-AG
influences the hypothalamic reward system.
Methods: The conditioned place preference test (CPP test) was used to evaluate HFD preferences. Hypothalamic 2-AG was
quantified by gas chromatography-mass spectrometry. The expression of GFAP was examined by immunostaining and
western blotting.
Results: Consumption of a HFD over either 3 or 7 days increased HFD preferences and transiently increased hypothalamic 2-
AG levels. HFD consumption over 14 days similarly increased HFD preferences but elicited a long-lasting increase in
hypothalamic 2-AG and GFAP levels. The cannabinoid 1 receptor antagonist O-2050 reduced preferences for HFDs after 3, 7,
or 14 days of HFD consumption and reduced expression of GFAP after 14 days of HFD consumption. The astrocyte
metabolic inhibitor Fluorocitrate blocked HFD preferences after 14 days of HFD consumption.
Conclusions: High levels of 2-AG appear to induce HFD preferences, and activate hypothalamic astrocytes via the
cannabinoid system. We propose that there may be two distinct stages in the development of HFD preferences. The
induction stage involves a transient increase in 2-AG, whereas the maintenance stage involves a long lasting increase in 2-
AG levels and activation of astrocytes. Accordingly, hypothalamic 2-AG may influence the development of HFD preferences.
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Introduction
Subjects often choose to consume a high-fat diet (HFD) over
other diets; this is called a HFD preference. Many reports have
shown that rats and mice exhibit spontaneous HFD preferences
[1,2]. Excessive consumption of HFDs induces life-style related
diseases including obesity, diabetes, and hyperlipidemia. The
etiology of HFD preferences has not yet been fully elucidated but it
is known that HFD preferences often induce excessive consump-
tion of HFDs. Several studies have indicated that food reward,
such as the consumption of a HFD, is controlled by the
endogenous brain reward system [1,2,3,4,5]. It is thought that
preferences for HFDs are attributable to numerous endogenous
factors that are related to the reward system. We focused on the
cannabinoid system as a potential mediator of HFD preferences
because cannabinoids are involved in physiological processes
related to memory, reward-related feeding, energy balance, and
related processes [5,6,7,8,9,10,11,12,13]. Previously, we reported
that the brain levels of the endocannabinoid 2-arachidonoylgly-
cerol (2-AG), which is a full agonist of cannabinoid 1 (CB1)
receptors, are increased in mice with HFD preferences [14].
Moreover, our data suggested that the development of preferences
for HFDs requires the activation of hypothalamic astrocytes via
CB1 receptors [15]. Therefore, 2-AG may be intimately involved
in the relationship between HFD preferences and the brain reward
system. From these findings, in this study we hypothesized that 2-
AG may influence the hypothalamic reward system and the
process of developing a HFD preference.
The cannabinoid system, which includes CB1 receptors and 2-
AG, has been known to play a major role in the regulation of
reward and appetite [5,6,7,8,10,11,12,13]. Recently, blockade of
CB1 receptors has been shown to suppress appetite and
consumption of attractive diets such as HFDs, sweet food, and
alcohol [13,16,17,18,19,20,21,22]. We reported that hypothalamic
2-AG is increased in the mice with a HFD preference, and the
CB1 receptors antagonist O-2050 reversed HFD preferences [14].
CB1 receptors are found in the hypothalamus [23,24]. In addition,
recent findings indicate that direct infusion of CB1 receptor
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2antagonists into the hypothalamus attenuates food consumption
and appetite [17]. From these data, we hypothesized that the
hypothalamic cannabinoid system plays important roles in HFD
preferences. In this study, we used the conditioned place
preference test (CPP test) to evaluate preferences for HFDs. The
CPP test has been used to evaluate the rewarding effects of
addictive drugs and highly palatable diets [1,25,26,27,28,29]. The
CPP test measures rewarding effects based on the subject’s
preference for a specific environment that has been previously
paired with an appetitive stimulus. In this study, we quantified the
levels of hypothalamic 2-AG before and after the CPP test to
examine the relationship between the preference for a HFD and
hypothalamic 2-AG.
In a previous study, our data suggested that hypothalamic
astrocytes may be involved in the development of preferences for
HFDs via activation of CB1 receptors [15]. Astrocytes are non-
neuronal cells in the brain, and they regulate neurotransmission
[30,31,32]. Furthermore, recent studies show that activated
astrocytes are involved in drug abuse [33,34,35,36]. These reports
suggest the possibility that astrocytes may play important roles in
the reward system. However, there is no direct evidence of a
relationship between astrocytes and rewarding effects. To this end,
in the present study, we used the astrocyte metabolic inhibitor
fluorocitrate (FC) to directly examine the relationship between
astrocytes and HFD preferences.
Results
To evaluate HFD preferences, after HFD or SD consumption,
the CPP test was conducted. Animals that had consumed a HFD
for 1 day prior to CPP test, did not show a HFD preference. In
contrast, animals that had consumed a HFD for 3 days prior to
CPP conditioning showed a significant preference for the HFD
compared with animals that had consumed a SD (group: F(1,
14)=38.569, p,0.001, day: F(5, 70=1.172, p=0.331, group x
day: F(5, 70)=1.153, p=0.340, two-way ANOVA,
*p,0.05,
Student’s t-test, Figure 1(a)). Next, we quantified the levels of
hypothalamic 2-AG before and after the CPP test. At 3 and 7 days
intake, the 2-AG levels after the test were significantly higher
compared with HFD and SD intake group. The 2-AG levels after
the test were significantly higher compared with before the test in
the animals that had consumed a HFD for 3 and 7 days (3-day
intake; F(3,20)=9.620, 7-day intake; F(3,25)=15.265,
*p,0.05,
Tukey-Kramer tests, Figure 1(b)). Moreover, animals that had
consumed a HFD for 14, 28 and 42 days exhibited higher 2-AG
levels before the test compared with animals that had not
consumed a HFD, regardless of whether they had undergone
the CPP test. The 2-AG levels after the test were significantly
higher compared with HFD and SD intake group (14-day intake;
F(3,24)=14.566, 28-day intake; F(3,17)=9.980, 42-day HFD
intake; F(3,18)=6.040,
*p,0.05, Tukey-Kramer tests, Figure 1(b)).
On the other hand, the 2-AG levels were not changed in SD intake
group, regardless of whether they had undergone the CPP test
(Figure 1(b)). The levels of astrocytes were examined to evaluate
the effects of HFD consumption on the hypothalamus using the
anti-GFAP antibody. Hypothalamic GFAP were increased. As
determined by western blotting, the expression of GFAP was
significantly increased after 14 days of HFD consumption, but not
3 days (
*p,0.05, Student’s t-test, Figure 2(b)). The CB1 receptors
antagonist O-2050 was used to examine the relationship between
HFD preferences and the cannabinoid system. The administration
of O-2050 (single injection, 10 mg/kg i.p.) before the CPP test
suppressed HFD preferences in the animals that had consumed a
HFD for 3 days (
*p,0.05, Student’s t-test, Figure 3 (a)). The
preference for a HFD in the animals that had consumed a HFD
for 14 days was suppressed by the 14-day administration of O-
Figure 1. Preference scores and hypothalamic 2-AG after SD or HFD consumption. (a) Filled circles represent the preference score in HFD
intake mice. Open circles represent the preference score in SD intake mice. Preference score represents the mean change in time (s) spent in the HFD-
paired side in pre-test and test sessions. n=8 for each. Results are expressed as the mean 6 S.E.M. *p,0.05 vs. SD consumption group (Student’s t-
test were performed following two-way ANOVA). (b) Mice were given HFD (+) or SD (-) before the CPP test. Hypothalamic 2-AG were quantified by
GC-MS. Filled squares represents the hypothalamic 2-AG after test. Open squares represents the hypothalamic 2-AG before test. n=8 for each. Results
are expressed as the mean 6 S.E.M.
doi:10.1371/journal.pone.0038609.g001
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administration of O-2050 before the CPP test (
*p,0.05, Student’s
t-test, Figure 3 (b)). Next, we tested whether O-2050 affected
hypothalamic GFAP expression after 14 days of HFD consump-
tion. The 14-day administration of O-2050 decreased the
expression of GFAP in the hypothalamus ({p,0.05, Student’s t-
test, Figure 3(b)). Finally, we examined the direct relationship
between hypothalamic GFAP expression and HFD preferences
using FC. The administration of FC significantly decreased
preferences for a HFD in the animals that had consumed a
HFD for 14 days (F(2.31)=9.885,
*p,0.05, Tukey-Kramer tests,
Figure 4(b)), but not in the animals that had consumed a HFD for
3 days (Figure 4(a)).
Discussion
In this study, we found that there are two stages in the
development of HFD preferences and the hypothalamic reward
system is dynamically changed during the development of these
preferences. During the first 3 days of HFD consumption,
hypothalamic 2-AG was transiently increased, possibly by the
rewarding effects of a HFD. Over 14 days of HFD consumption,
2-AG levels and the number of GFAP-IR astrocytes in hypothal-
amus were persistently increased. Taken together, we suggest that
there is both an induction (over the first 3 days) and a maintenance
phase (over the first 14 days) in the development of a HFD
preference.
In this study, after 3 days of HFD consumption, the mice
exhibited a HFD preference. On the other hand, SD fed mice did
not show a HFD preference. Some studies indicate that HFD
preference was developed in CPP test [1,37]. However, in these
studies, the conditioning was conducted more than 3 times. In this
study, we conducted 2 times conditioning. Therefore, we con-
cluded that 2 times HFD conditioning was enough to recognize
the HFD paired-box, but did not develop the HFD preference.
The CPP test was used widely to evaluate the several rewarding
effects [1,25,26,27,28,29]. However, it is difficult to examine the
process of rewarding effects because mice were given HFD only
during the conditioning period. As such, we used a previously
described and modified CPP test [14,15]. The mice were given the
HFD or SD before the CPP test, and we assessed their preference
by comparing the time spent in the HFD-paired side at baseline
and following conditioning in each group (HFD consumption and
SD consumption). Previously, we reported that this method is a
Figure 2. The expression of GFAP in the hypothalamus after HFD consumption. (a) Immunostaining of GFAP after 0, 3, or 14 days of HFD
intake in the hypothalamus Abbreviations: 3 V: 3rd ventricle; DMH: dorsomedial hypothalamic nucleus; VMH: ventromedial hypothalamic nucleus.
Scale bar: 100 mm. (b) The expression of GFAP after 3 or 14-day HFD intake. n=6 for each. Results are expressed as the mean 6 S.E.M.
*p,0.05 vs. SD
(Student’s t-test).
doi:10.1371/journal.pone.0038609.g002
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[14]. In this study, we examined the progress of a long-term HFD
preference, for the first time.
In the animals that consumed the HFD for 3 or 7 days,
hypothalamic 2-AG was significantly increased after the CPP test.
However, there was no significant increment of 2-AG before the
CPP test. Thus, the hypothalamic 2-AG may be increased by
reinforcing effect of HFD. A recent study showed that levels of
endocannabinoids in the hypothalamus were increased during
hunger [20]. Levels of 2-AG have been shown to be regulated by
leptin or glucose [38,39]. In this study, mice were not deprived of
food. There is the possibility that other factors regulate 2-AG levels
when an animal has a HFD preference. Mizushige et al. reported
that mRNA levels of proopiomelanocortin, a beta-endorphin
precursor, are increased by the anticipation of consuming oil, and
beta-endorphin is rapidly released after oil ingestion in oil-
preferring rats [3,4]. An increasing number of studies indicate that
cannabinoids and opioids use partially overlapping mechanisms to
modulate physiological processes, including reward and appetite
[5,18]. Thus, the high levels of 2-AG after the CPP test may be
related to cannabinoid-opioid cross-talk. Further studies are
needed to determine why 2-AG is increased transiently in the
hypothalamus.
On the other hand, after 14 days of HFD consumption,
hypothalamic 2-AG was significantly increased before the CPP
test, and 2-AG levels were not changed after CPP test. And, the
number of astrocytes was markedly increased in the hypothala-
mus. However, the number of neurons and microglia were not
significantly changed by any duration of HFD consumption
examined (data not shown). It is known that astrocytes are
proliferated by cannabinoid-system [40]. Furthermore, cannabi-
noids are synthesized in astrocyte, not only in neurons [41].
Therefore, persistent increment of 2-AG may proliferate the
hypothalamic astrocyte via cannabinoid-system.
To elucidate the relationship between the cannabinoid system
and each stage of the development of HFD preferences, we
examine the effects of the CB1 receptor antagonist, O-2050. The
induction of a HFD preference (over 3 days) was attenuated by a
single administration of O-2050 (before the CPP test). Accumu-
lating studies show that CB1 receptor antagonists inhibit the
acquisition of rewarding effect [13,18,19,20,21,22]. In this study,
our results suggest that activation of hypothalamic CB1 receptors
by the transient increase in 2-AG levels during HFD conditioning
is required for the induction of a HFD preference.
However, the HFD preferences that developed over 14 days of
HFD consumption were attenuated by 14-day administration of
Figure 3. Effects of the CB1 receptor antagonist O-2050 on HFD preferences. (a) Mice were given HFD for 3 days before CPP test. O-2050
(10 mg/kg i.p.) was administrated 1 h before the test. n=8 for each. Results are expressed as the mean 6 S.E.M.
*p,0.05 vs. Vehicle (Student’s t-test).
(b) Mice were given HFD for 14 days before CPP test. O-2050 (10 mg/kg i.p.) was administrated 1h before the test (test day) or for 14 days before the
CPP test (14 days). n=8 for each (CPP test). n=6 for each (western blotting). Results are expressed as the mean 6 S.E.M. Scale bar: 100 mm.
*p,0.05
vs. Vehicle (Student’s t-test).
doi:10.1371/journal.pone.0038609.g003
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noted that the expression of GFAP in the animals that consumed a
HFD for 14 days was suppressed by 14-day administration of O-
2050. It is known that astrocyte has CB1 receptors [41,42]. The
increment of 2-AG by HFD intake or rewarding effect might
activate the hypothalamic astrocyte and developed HFD prefer-
ence. Several studies show that astrocytes proliferate following
cannabinoid stimulation and this is related to drug abuse and
rewarding effects [33,34,35,36,40,43]. Our results indicate that the
development of a HFD preference in these animals required
alteration of hypothalamic astrocytes to elicit long-term CB1
receptor activation. Thus, we suggest that an increase in
hypothalamic astrocytes by 14 days of HFD consumption may
be involved in the maintenance of a HFD preference.
Finally, we examined whether astrocytes mediate HFD prefer-
ences directly. In this regard, we previously reported that 1 nmol/
site of FC can suppress astrocytic metabolism without neuronal
damage [44]. We administrated the FC to dorsomedial hypotha-
lamic nucleus (DMH), because astrocytes were activated in DMH.
In this study, FC attenuated HFD preferences in the animals that
consumed a HFD for 14 days, but not those that consumed a
HFD for 3 days. In other words, FC suppressed HFD preference
with activated astrocytes, and did not suppress HFD preference
with non-activated astrocytes. Based on these results, we conclude
that the maintenance of a HFD preference is mediated by GFAP-
IR activated astrocytes via cannabinoid system. Thus, astrocyte
proliferation and concomitant activation of CB1 receptors is
directly involved in the development of HFD preferences over
14 days of HFD consumption. Accumulating data have shown
that astrocytes are involved in many aspects of neuron-astrocyte
interactions (e.g., the uptake and metabolism of glutamate, the
dynamic sensing of neurotransmitters and neuromodulators, and
the release of neuroactive factors) [31,32,45,46,47,48,49]. Recent
studies suggest that astrocytes mediate rewarding effects including
drug abuse via modulating glutamate [33,34,43]. Moreover,
recent studies revealed that glutamatergic neurons and orexin in
the hypothalamus activated the ventral tegmental area (VTA)
[50,51,52]. Thus, activated astrocytes may activate hypothalamic
orexin neurons via release of glutamate, and promote the
rewarding processing. Additionally, astrocytes regulate the matu-
ration of dendritic spines by direct contacts [53]. Our immuno-
staining results suggested that 14 days HFD intake induced the
growth of astrocyte foot process. The astrocyte foot process may
develop the maturation of dendritic spines to keep the HFD
preference.
Based on our results (Fig. 1(b), Fig. 3 and Fig. 4), it is
conceivable that the reward system’s role in HFD preferences is
different over 3 or 14 days of HFD consumption. Over the first
3 days, the induction of HFD preferences appears to be related to
transient increases in hypothalamic 2-AG levels. Over the first
14 days, the maintenance of HFD preferences appears to be
related to persistent increases in astrocyte levels and concomitant
increases in CB1 receptor activation. The process of developing
HFD preferences is still debatable, but our results indicate this
process has both an induction and a maintenance phase. This is
the first time that a multistage process of developing preferences
for HFDs has been proposed.
Methods and Materials
Ethics Statement
All animal care and use procedures were performed in
compliance with the regulations established by the Experimental
Animal Care and Use Committee of Fukuoka University followed
the Guidelines of the Science Council of Japan (approved no.
1007411 of institutional review board).
Animals
Male ICR mice (25–35 g, Kyudo Experimental Animal
Laboratory, Saga, Japan) were kept under a 12 h light/dark cycle
(lights on from 07:00 to 19:00 h) in an air-conditioned room
(2362uC). They were fed a HFD (F2HFD1, Oriental Yeast Co,
Tokyo, Japan) or a standard diet (SD) (CE-2, Clea Japan, Tokyo,
Japan), and water was available ad libitum. The composition of
each diet was as follows: fat, SD: 4.8 g/100 g (soybean-based),
Figure 4. Effects of FC on preferences for a HFD. Results are expressed as the mean 6 S.E.M. (a) The mice were fed a HFD for 3 days before the
CPP test. (Vehicle, n=10; 0.1 nmol/site, n=10; 1.0 nmol/site, n=11). (b) The mice were fed a HFD for 14 days before the CPP test. (Vehicle, n=14;
0.1 nmol/site, n=12; 1.0 nmol/site, n=16).
*p,0.05 vs. Vehicle (Tukey-Kramer tests).
doi:10.1371/journal.pone.0038609.g004
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100 g, HFD: 414 kcal/100 g.
Conditioned place preference (CPP) test
The CPP test was used to evaluate HFD preferences. Details of
the CPP test were described previously [14,15]. Mice were fed an
SD or HFD before conducting the CPP test. Throughout the CPP
test, mice ate about 3.4 g of the SD (nearly 10 kcal/day), which
represents approximately 68% of the daily food consumption of
mice fed ab libitum in similar housing conditions (about 14.7 kcal/
day or 5.0 g of SD). A test chamber consisting of two sides of equal
size (15615615 cm) was used for the CPP test. The walls of the
dark side were black, and the light side was white. Both sides were
equipped with a grid floor, and a hatched transparent sheet was
placed on the grid of the dark side. The CPP test consisted of 3
stages. The pre-test was conducted on Day 1, the conditioning
during Days 2–5, and the test on Day 6. In both the pre-test on
Day 1 and the test on Day 6, each mouse was placed in the CPP
apparatus and allowed free access to the light and dark sides in the
absence of food for 15 min. The times spent in the light or dark
side, respectively, were measured. During the conditioning on
Days 2–5, each mouse was confined to the light or dark side for
30 min, respectively, in the presence of the SD or the HFD. Equal
amounts of the SD or the HFD was offered to the mice during
conditioning. Preference scores were expressed as the change in
the time spent in the HFD-paired side before and after
conditioning.
Quantification of 2-AG
The levels of hypothalamic 2-AG were quantified by gas
chromatography-mass spectrometry (GC-MS) as previously de-
scribed [14,54]. The tissues were isolated immediately after the
CPP test. The hypothalamus was homogenized in 5 volumes of
chloroform/methanol/Tris HCl buffer (50 mM, 2:1:1) containing
butylated hydroxytoluene (BHT) (final, 0.05%) and 5 mgo f
URB602, which was added to block monoacylglycerol lipase
activity. Homogenates were centrifuged at 20,400 g for 5 min
(5uC). The aqueous phase and debris were collected and extracted
twice with 1 volume of chloroform. The organic phases from the
three extractions were pooled. The organic phase was dried under
nitrogen before further purification. The organic phase was
purified using Sep-Pak C-18 cartridges. The Sep-Pak C-18
cartridges were conditioned with 4 mL of methanol followed by
a wash with 4 mL of water. Dried samples were diluted with
1.5 mL of acetone and 8 mL of water. After passing the sample,
the cartridge was washed with 2 mL of acetone/water (20:80), and
the 2-AG was eluted with 5 mL of diethyl ether. The internal
standard (IS), methyl heneicosanoate (50 ng), was added to 2-AG
after C18 solid-phase extraction. The eluted solution was dried
under nitrogen prior to derivatization. The 2-AG-containing
fractions were derivatized by treatment with 30 mL of BSTFA at
room temperature for 30 min. Derivatized samples were dried
under nitrogen, resuspended in 20 mL of acetonitrile, and injected
(splitless mode) into a GC-MS. A GCMS-QP2010 (Shimadzu,
Kyoto, Japan) equipped with a AOC-20i autosampler (Shimadzu,
Kyoto, Japan) was used for analysis in the positive electron
ionization (EI) mode. GC-MS conditions were as follows: column,
DB-5MS fused silica capillary column (30 m60.25 mm i.d.,
0.25 mm J&W scientific); column oven program, 10uC for 1 min
followed by an increase to 290uCa t1 0 uC/min. Injector
temperature, 290uC; helium at a constant flow rate of 1.33 mL/
min. The following ions were used for selected ion monitoring
(SIM) analyses: 2-AG (m/z 522 for [M]
+, m/z 507 for [M-
methyl]
+, m/z 432 for [M-TMSOH]
+).
Pharmacological effect of CB1 receptor antagonist, O-
2050
O-2050 (TOCRIS, Ellisville, MO, USA) was dissolved in 1%
Tween 80. O-2050 (10 mg/kg) and 1% Tween 80 (vehicle) were
administered i.p. for 14 days (14-day) or 1 h before the Day 6
CPP test (test day).
Immunostaining
Mice were perfused with saline and 4% paraformaldehyde.
Their brains were cleared of fat and water using an auto
degreasing unit (RH-12, Sakura Seiko, Tokyo, Japan) and then
embedded in paraffin. Subsequently, 5-mm-thick sections were
mounted on slides and dried at 37uC for 1 day. After
deparaffinization and rehydration, sections were incubated in
Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBS-T) for
30 min. The sections were incubated with a blocking solution (3%
goat serum) for 30 min at room temperature. Sections were then
incubated overnight at 4uC with primary antibody (1:500 rabbit
glial fibrillary acid protein (GFAP)-antibody (Ventana AZ, USA)
in blocking solution). The sections were stained using the avidin-
biotin-peroxidase method. The sections were washed three times,
incubated with goat anti-mouse or rabbit IgG for 1 h, washed
again, and processed using the Vecstain ABC kit (Vector Labs,
Burlingame, CA). They were immersed for 20–30 min in 0.05%
diaminobenzidine, 0.05% H2O2, and imidazole buffer and then
mounted on poly-L-lysine coated slides.
Immunoblotting
The expression of GFAP protein was evaluated by western
blotting following sample extraction by SDS-PAGE as described
previously. Tissue samples were homogenized at 4uC for 1 min in
lysis buffer with a protease inhibitor cocktail. Tissue extracts were
centrifuged at 15,000 rpm at 4uC for 30 min. The same procedure
was followed for the supernatant. SDS sample buffer was added to
aliquots of tissue extracts containing 15 mg of total protein.
Proteins were separated by SDS-PAGE (12–15% gel). Blotting was
performed using a semi-dry method (BIORAD, Hercules, CA).
The blots were blocked with 5% non-fat dry milk at 4uC, and
incubated with anti-GFAP polyclonal antibodies (1:200) in TBS-T,
followed by goat anti-rabbit IgG AP conjugate (1:1000) in TBS-T
and bovine anti-goat IgG AP conjugate (1:1000) in TBS-T. The
blots were visualized by AP color reagents. The signal intensity of
the blots was measured by an image analysis system (NIH Image,
version 1.63).
Pharmacological effects of FC
To test the hypothesis that the development of HFD preferences
is directly related to astrocytes, we metabolically inhibited
astrocytes using FC. The FC solution for intrahypothalamic
injections was prepared by dissolving 8 mg of D, L-fluorocitric
acid, Ba, salt (Sigma-Aldrich, St Louis, MO) in 1 ml of 0.1 mmol/
L HCL. Two to three drops of 0.1 mmol/L Na2SO4 were added
to precipitate the Ba
2+. Two milliliters of 0.1 mmol/L Na2HPO4
was added, and the suspension was centrifuged at 1,000 g for
5 mins. The supernatant was diluted with 0.9% NaCl to the final
concentration, and the pH was adjusted to 7.4. Stereotaxic surgery
was carried out under sodium pentobarbital (50 mg/kg, i.p.;
Tokyo Kasei, Tokyo Japan), and guide cannulas was stereotax-
ically implanted into DMH region (anterior: 21.70 mm from
Bregma; lateral: 0.5 mm from Bregma; depth: 5 mm from the
skull surface) before HFD intake. We administrated the FC
according to our previously described methods and those of
Paulsen et al [44,55,56]. The FC solution was microinjected into
The Role of 2-AG in HFD Preferences
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was injected continuously at a rate of 0.25 mL/min through a
stainless steel cannula (28 gauge) connected to a 25-mL syringe
driven by a slow-injection pump. At the completion of testing,
brains were extracted and fixed in formalin. The brains were then
sectioned with a sliding microtome, stained with cresyl violet, and
mounted onto microscope slides for confirmation of injection sites.
Miss injected mice were eliminated from the results.
Statistical Analysis
Results are expressed as the mean 6 the standard error of the
mean (S.E.M.) Student’s t-tests and Tukey-Kramer tests were used
to determine statistically significant differences. Student’s t-test
were performed following two-way ANOVA for the CPP test.
P,0.05 was considered to be statistically significant.
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